The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics

Fitzgerald, Kathleen A.; Guo, Jianfeng; Tierney, Erica G.; Curtin, Caroline M.; Malhotra, Meenakshi; Darcy, Raphael; O’Brien, Fergal J.; O’Driscoll, Caitriona M.

doi:10.1016/j.biomaterials.2015.07.019

Cited by 96 publications

(85 citation statements)

References 91 publications

(106 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The highly metastatic C4-2 cell line exhibited a greater mobility on both collagen I and laminin than on plastic, corresponding to the metastatic behavior of the C4-2 cells in the progression model (20). Similarly, the bone-adaptive C4-2B cell line was shown to migrate dramatically faster on collagen I, which is a major ECM component found in the bone microenvironment (28) and is associated with PCa metastasis (39). These preferential migrations of PCa cell lines on each ECM protein corresponded to the progression of this model from non-metastatic PCa (LNCaP) to metastatic PCa (C4-2) and eventually, bone-adaptive PCa (C4-2B).…”

Section: Discussionmentioning

confidence: 94%

Purinergic Receptor Expression and Cellular Responses to Purinergic Agonists in Human Prostate Cancer Cells

Lertsuwan

Peters

Johnson

et al. 2017

View full text Add to dashboard Cite

Extracellular nucleotides were first proposed as signaling molecules in 1972 (1). Signaling through purinergic receptors is ubiquitous due to the diversity of purine and pyrimidine ligands, the number of receptors and extracellular nucleotidases. Purinergic signaling has been shown to play a role in many pathways including neurotransmission (2), cell differentiation, hormone secretion, vasodilation, cell proliferation, wound healing and apoptosis (3). There are two distinct families of purinergic receptors: P1 receptors for adenosine and P2 receptors for ATP/ADP and UTP/UDP ligands. P2 receptors are further divided into ligand-gated ion channel receptors, P2X, and G protein-coupled receptor, P2Y, subfamilies. To date, four P1 receptors (A 1,2a,2b,3 ), seven P2X receptors (P2X 1-7 ) and eight P2Y receptors (P2Y 1,2,4,6,11-14 ) have been identified in mammalian cells (4). The adenosine receptor subtypes A 1 and A 3 downregulate the production of cAMP, while A 2a and A 2b subtypes up-regulate the production of cAMP. Activation of P2X receptors leads to an influx of cations from the extracellular space, while activation of P2Y receptors leads to either an elevation of intracellular Ca 2+ from endoplasmic reticulum stores or down-regulation of cAMP production depending on the specific subtype of P2Y receptor activated.Growth suppression by the P2 agonist, ATP, was demonstrated first by Rapaport in 1983 (5). Exogenous ATP was shown to suppress the growth of pancreatic and colon cancer by causing cell-cycle arrest in S-phase. To date, the anticancer activity of extracellular nucleotides has been investigated in many types of cancer, including leukemia, melanoma and non-melanoma skin cancer, colorectal cancer, lung cancer, cervical cancer, prostate cancer (PCa) and squamous cell skin cancer (6). These led to clinical trials in patients with colorectal and non-small cell lung cancer that showed promising results with limited side-effects (7-9).PCa is the most frequently diagnosed cancer in North American men and the second leading cause of cancerrelated death in American men. It was estimated that there would be approximately 180,890 new cases of PCa and 26,5120 related deaths in the United States alone in 2016 (10). Current standard treatments for advanced PCa include various hormonal therapies whose goal is the ablation of androgens and their action (11). Even though 70% to 80% of patients respond well to first-line treatment, most patients eventually develop castrate-resistant disease (CRPCa) (12). Novel therapy therefore is needed to eliminate both early and 529 Τhis article is freely accessible online.

show abstract

Section: Discussionmentioning

confidence: 94%

Purinergic Receptor Expression and Cellular Responses to Purinergic Agonists in Human Prostate Cancer Cells

Lertsuwan

Peters

Johnson

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Recently a collagen scaffold-based 3D prostate cancer bone metastasis model was established to evaluate gene delivery [73]. Non-viral delivery vectors, including Lipofectamine and a modified cyclodextrin, facilitated gene knockdown in this 3D model [73]. In a study by Xu et al (2014), a hyaluronic-acid based hydrogel was used to evaluate the anticancer effect of doxorubicin [74].…”

Section: Hyaluronan Hydrogelmentioning

confidence: 99%

Section: Hyaluronan Hydrogelmentioning

confidence: 99%

Life in 3D is never flat: 3D models to optimise drug delivery

Fitzgerald

Malhotra

Curtin

et al. 2015

Journal of Controlled Release

Self Cite

191

126

View full text Add to dashboard Cite

“…Thus, 3D culture may be a powerful tool in tumor and relevant drug research. Marked advances have been made in the basic development of 3D tumor models so far, and prominent studies using 3D tumor cell models to simulate the tumor microenvironment or assess drug delivery in the past 5 years are summarized in Table I (6,8,(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35). Considering the advantages of 3D tumor models, the present review provides an overview of the methods and techniques successfully devised for practicing 3D tumor cell culture.…”

Section: Current Preclinical Tumor Modelsmentioning

confidence: 99%

Three‑dimensional cell culture: A powerful tool in tumor research and drug discovery (Review)

Lv¹,

Hu²,

Lü³

et al. 2017

Oncol Lett

268

296

View full text Add to dashboard Cite

Abstract. In previous years, three-dimensional (3D) cell culture technology has become a focus of research in tumor cell biology, using a variety of methods and materials to mimic the in vivo microenvironment of cultured tumor cells ex vivo. These 3D tumor cells have demonstrated numerous different characteristics compared with traditional two-dimensional (2D) culture. 3D cell culture provides a useful platform for further identifying the biological characteristics of tumor cells, particularly in the drug sensitivity area of the key points of translational medicine. It promises to be a bridge between traditional 2D culture and animal experiments, and is of great importance for further research in the field of tumor biology. In the present review, previous 3D cell culture applications, focusing on anti-tumor drug susceptibility testing, are summarized.

show abstract

The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics

Cited by 96 publications

References 91 publications

Purinergic Receptor Expression and Cellular Responses to Purinergic Agonists in Human Prostate Cancer Cells

Purinergic Receptor Expression and Cellular Responses to Purinergic Agonists in Human Prostate Cancer Cells

Life in 3D is never flat: 3D models to optimise drug delivery

Three‑dimensional cell culture: A powerful tool in tumor research and drug discovery (Review)

Contact Info

Product

Resources

About